Last reviewed · How we verify
THIMEROSAL
At a glance
| Generic name | THIMEROSAL |
|---|---|
| Drug class | Standardized Chemical Allergen [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia (PHASE3)
- Efficacy of the Vacucis Candida® Autovaccine (NA)
- Safety and Immunogenicity Study of Thiomersal-free Hepatitis E Vaccine in People Ages 16 Years and Above (PHASE4)
- Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly (PHASE3)
- Immunological Characteristics of a Population at Risk of Cholera After Oral Cholera Vaccine (CHOVAXIM) (NA)
- Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine (PHASE3)
- A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19 (PHASE2)
- Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- THIMEROSAL CI brief — competitive landscape report
- THIMEROSAL updates RSS · CI watch RSS